Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7158)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2013 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kaneto H, Matsuoka TA. Down-regulation of pancreatic transcription factors and incretin receptors in type 2 diabetes. World J Diabetes 2013; 4(6): 263-269 [PMID: 24379916 DOI: 10.4239/wjd.v4.i6.263] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v4/i6/263.htm |
| Number | Citing Articles |
| 1 |
Joanne C. McNelis, Yun Sok Lee, Rafael Mayoral, Rik van der Kant, Andrew M.F. Johnson, Joshua Wollam, Jerrold M. Olefsky. GPR43 Potentiates β-Cell Function in Obesity. Diabetes 2015; 64(9): 3203 doi: 10.2337/db14-1938
|
| 2 |
J. Michael Conlon, Bosede O. Owolabi, Peter R. Flatt, Yasser H.A. Abdel-Wahab. Amphibian host-defense peptides with potential for Type 2 diabetes therapy – an updated review. Peptides 2024; 175: 171180 doi: 10.1016/j.peptides.2024.171180
|
| 3 |
Huan Li, Yixiang Li, Lingwei Xiang, JiaJia Zhang, Biao Zhu, Lin Xiang, Jing Dong, Min Liu, Guangda Xiang. GDF11 Attenuates Development of Type 2 Diabetes via Improvement of Islet β-Cell Function and Survival. Diabetes 2017; 66(7): 1914 doi: 10.2337/db17-0086
|
| 4 |
Xing Xu, Gaihong Wang, Tingting Zhou, Lili Chen, Jing Chen, Xu Shen. Novel approaches to drug discovery for the treatment of type 2 diabetes. Expert Opinion on Drug Discovery 2014; 9(9): 1047 doi: 10.1517/17460441.2014.941352
|
| 5 |
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, Andreas F. H. Pfeiffer. The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity and Metabolism 2021; 23(S3): 5 doi: 10.1111/dom.14496
|
| 6 |
Meenal Francis, Smitha Bhaskar, Sreya Vishnuvajhala, Jyothi Prasanna, Anujith Kumar. Dynamics of Ubiquitination in Differentiation and Dedifferentiation of Pancreatic β-cells: Putative Target for Diabetes. Current Protein & Peptide Science 2022; 23(9): 602 doi: 10.2174/1389203723666220422092023
|
| 7 |
Leonid E. Fridlyand, Louis H. Philipson, Tao Cai. Pancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational Analysis. PLOS ONE 2016; 11(5): e0152869 doi: 10.1371/journal.pone.0152869
|
| 8 |
Vishal Musale, R. Charlotte Moffett, J. Michael Conlon, Peter R. Flatt, Yasser H. Abdel-Wahab. Beneficial actions of the [A14K] analog of the frog skin peptide PGLa-AM1 in mice with obesity and degenerative diabetes: A mechanistic study. Peptides 2021; 136: 170472 doi: 10.1016/j.peptides.2020.170472
|
| 9 |
Gayathri Shama Bhat, Tarakad Ranganatha Keshav, Raghu Chandrashekar Hariharapura, Shaik Mahammad Abdul Fayaz. Interplay of miRNA-TF-Gene Through a Novel Six-node Feed-forward
Loop Identified Inflammatory Genes as Key Regulators in Type-2 Diabetes. Current Bioinformatics 2024; 19(1): 73 doi: 10.2174/1574893618666230731164002
|
| 10 |
Tijun Wu, Shuang Zhang, Jialiang Xu, Yaqin Zhang, Tong Sun, Yixue Shao, Jiahui Wang, Wei Tang, Fang Chen, Xiao Han. HRD1, an Important Player in Pancreatic β-Cell Failure and Therapeutic Target for Type 2 Diabetic Mice. Diabetes 2020; 69(5): 940 doi: 10.2337/db19-1060
|
| 11 |
Milica Markelic, Ana Stancic, Tamara Saksida, Ilijana Grigorov, Dragica Micanovic, Ksenija Velickovic, Vesna Martinovic, Nevena Savic, Andjelija Gudelj, Vesna Otasevic. Defining the ferroptotic phenotype of beta cells in type 1 diabetes and its inhibition as a potential antidiabetic strategy. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1227498
|
| 12 |
Tomohiko Kimura, Hideaki Kaneto, Masashi Shimoda, Hidenori Hirukawa, Seizo Okauchi, Kenji Kohara, Sumiko Hamamoto, Kazuhito Tawaramoto, Mitsuru Hashiramoto, Kohei Kaku. Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes. Molecular and Cellular Endocrinology 2015; 400: 78 doi: 10.1016/j.mce.2014.11.018
|
| 13 |
Tomohiko Kimura, Atsushi Obata, Masashi Shimoda, Seizo Okauchi, Yukiko Kanda‐Kimura, Yuka Nogami, Saeko Moriuchi, Hidenori Hirukawa, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β‐cells in db/db mice: The earlier and longer, the better. Diabetes, Obesity and Metabolism 2018; 20(10): 2442 doi: 10.1111/dom.13400
|
| 14 |
Soroku Yagihashi, Wataru Inaba, Hiroki Mizukami. Dynamic pathology of islet endocrine cells in type 2 diabetes: β‐Cell growth, death, regeneration and their clinical implications. Journal of Diabetes Investigation 2016; 7(2): 155 doi: 10.1111/jdi.12424
|
| 15 |
Gaëtan Prévost, Arnaud Arabo, Marie-Anne Le Solliec, Justine Bons, Marie Picot, Julie Maucotel, Hind Berrahmoune, Mouna El Mehdi, Saloua Cherifi, Alexandre Benani, Emmanuelle Nédélec, Moïse Coëffier, Jérôme Leprince, Anneli Nordqvist, Valéry Brunel, Pierre Déchelotte, Hervé Lefebvre, Youssef Anouar, Nicolas Chartrel. Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice. American Journal of Physiology-Endocrinology and Metabolism 2019; 317(1): E147 doi: 10.1152/ajpendo.00540.2018
|